Specialty Generics Market Report 2026

Specialty Generics Market Overview

• Specialty Generics market size has reached to $107.14 billion in 2025 • Expected to grow to $214.22 billion in 2030 at a compound annual growth rate (CAGR) of 14.9% • Growth Driver: Surge In Chronic Diseases Spurs Demand For Specialty Generics Market • Market Trend: New Approval To Address The Critical Need For Medication • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Specialty Generics Market?

The specialty generics refer to generic versions of drugs used to describe expensive, intricate, or high-touch generic versions of medications. It requires substantial service participation to manage. This specialty generic includes biologics and biosimilars, which have separate regulatory routes. The majority of specialty medications are used to treat various malignancies, rheumatoid arthritis, and multiple sclerosis. The main route of administration of specialty generics are injectables, oral, and other route of administration. The injectables route of administration of specialty generics are utilized for various routes of drug administration, such as intravenous, subcutaneous, intradermal, intraperitoneal, intramuscular, and others to treat medical conditions ranging from cancer to autoimmune disorders. A hollow hypodermic needle is used to introduce a substance into the bloodstream during drug injection. The specialty generics are used during the indications of oncology, autoimmune diseases, infectious diseases, and other indication that are distributed through multiple channel which are retail pharmacies, specialty pharmacies, and hospital pharmacies.

What Is The Specialty Generics Market Growth Forecast?

The specialty generics market size is expected to see rapid growth in the next few years. It will grow to $214.22 billion in 2030 at a compound annual growth rate (CAGR) of 14.9%. The growth in the forecast period can be attributed to expansion of specialty generics portfolio, advancements in biologics manufacturing technology, increasing healthcare expenditure, growing demand for personalized therapies, rising collaborations between pharma companies and CDMOs. Major trends in the forecast period include growth in biologics and biosimilars adoption, expansion of specialty pharmacy services, personalized medicine integration, increasing regulatory compliance complexity, rise in chronic disease treatment demand.

What Is The Driver Of The Specialty Generics Market?

The surge in chronic diseases is expected to propel the demand for the specialty generic market. Chronic diseases are long-lasting sicknesses that often cannot be healed. However, it is occasionally curable and controllable. The changing lifestyle, eating habits, and not maintaining body weight are the reasons for chronic conditions; a few more prolonged chronic infections lead to cancerous risk. Growing exposure to these diseases raises the need for specialty generics for a patient to treat complex chronic diseases. For instance, in March 2025, according to GOV.UK, a UK-based non-profit government organization, the GP recorded type 2 diabetes prevalence in adults as 7.0% for those aged 17 and over in England in March 2024, which was an increase from 6.8% in March 2023. Therefore, the surge in chronic diseases is driving the specialty generic industry growth.

Key Players In The Global Specialty Generics Market

Major companies operating in the specialty generics market are Teva Pharmaceutical Industries Ltd., Endo International plc, Akorn Operating Company LLC, Mallinckrodt Pharmaceuticals, Dr. Reddy’s Laboratories Ltd., Fresenius Kabi Brasil Ltda, STADA Arzneimittel AG, Cipla Limited, Lupin Ltd, Aurobindo Pharma Limited, Aspen Pharmacare Holdings Limited, Pfizer Inc., Accord Healthcare Limited, Amneal Pharmaceuticals Inc., Sandoz International GmbH, Zydus Lifesciences Ltd., Torrent Pharmaceuticals Ltd., Perrigo Company plc, Impax Laboratories Inc., Par Pharmaceutical Companies Inc., Alvogen, Alkem Laboratories Ltd., Wockhardt Ltd., Strides Pharma Science Limited, Indoco Remedies Ltd., Unichem Laboratories Ltd., Alembic Pharmaceuticals Ltd., Jubilant Life Sciences Ltd.

Global Specialty Generics Market Trends and Insights

Major companies operating in the specialty generic market are receiving approval for drugs such as Lisdexamfetamine Dimesylate to address the critical need for medication. Approval in specialty generics refers to the regulatory authorization granted to pharmaceutical products that are bioequivalent and therapeutically equivalent to brand-name specialty drugs, typically used in the treatment of complex or rare medical conditions, after the expiration of their patent protection. For instance, in August 2023, Mallinckrodt plc, an Ireland-based specialty pharmaceutical company, received FDA approval for its Lisdexamfetamine Dimesylate Capsules in the SpecGx LLC Specialty Generics segment to treat Attention-Deficit/Hyperactivity Disorder (ADHD). Lisdexamfetamine dimesylate is a type of specialty generic and a federally controlled substance (CII) used to treat ADHD and other indications.

What Are Latest Mergers And Acquisitions In The Specialty Generics Market?

In March 2025, Mallinckrodt Pharmaceuticals, an Ireland-based provider of specialty pharmaceuticals, specialty generics, sterile injectables, and active pharmaceutical ingredients (APIs), merged with Endo Inc. for an enterprise value of approximately US$6.7 billion. Through this merger, the companies aim to combine their specialty generics and sterile injectables capabilities, creating operational synergies in manufacturing, regulatory compliance, and R&D while planning a future spin-off of the combined generics and sterile injectables business as a standalone entity. This merger underscores the specialty generics market’s ongoing consolidation and strategic focus on high-barrier, complex generics and sterile injectable products. Endo Inc., a US-based provider of generics and sterile injectable products.

What Defines the Specialty Generics Market?

The specialty generics market consists of sales of biologics and biosimilars. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Specialty Generics Market Report 2026?

The specialty generics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the specialty generics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.